BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18984419)

  • 1. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
    Carsons SE
    Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab and primary Sjogren's syndrome: comment on the article by Mariette et al.
    Fresko I; Seyahi E; Yurdakul S
    Arthritis Rheum; 2004 Dec; 50(12):4077; author reply 4077-8. PubMed ID: 15593208
    [No Abstract]   [Full Text] [Related]  

  • 3. Recognition and management of Sjögren's syndrome: strategies for the advanced practice nurse.
    Vale DL
    Nurs Clin North Am; 2000 Mar; 35(1):267-78. PubMed ID: 10673580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will targeting B cells be the answer for Sjögren's syndrome?
    Looney RJ
    Arthritis Rheum; 2007 May; 56(5):1371-7. PubMed ID: 17469093
    [No Abstract]   [Full Text] [Related]  

  • 5. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome.
    Price EJ; Rigby SP; Clancy U; Venables PJ
    J Rheumatol; 1998 May; 25(5):896-9. PubMed ID: 9598887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sjögren's syndrome: a new approach to treatment].
    Rossier V; Bart PA; Spertini F
    Rev Med Suisse; 2012 Apr; 8(337):843-7. PubMed ID: 22594008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.
    Fauchais AL; Ouattara B; Gondran G; Lalloué F; Petit D; Ly K; Lambert M; Launay D; Loustaud-Ratti V; Bezanahari H; Liozon E; Hachulla E; Jauberteau MO; Vidal E; Hatron PY
    Rheumatology (Oxford); 2010 Jun; 49(6):1164-72. PubMed ID: 20299380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Sjogren's syndrome: current and prospective therapies.
    Thanou-Stavraki A; James JA
    Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.
    Carsons SE; Vivino FB; Parke A; Carteron N; Sankar V; Brasington R; Brennan MT; Ehlers W; Fox R; Scofield H; Hammitt KM; Birnbaum J; Kassan S; Mandel S
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):517-527. PubMed ID: 27390247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients presenting with Sjogren's syndrome.
    Venables PJ
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):791-807. PubMed ID: 16979538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and regression within primary Sjögren's syndrome.
    Manthorpe R; Bredberg A; Henriksson G; Larsson A
    Scand J Rheumatol; 2006; 35(1):1-6. PubMed ID: 16467033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of Sjogren's syndrome with rituximab.
    Touma Z; Sayad J; Arayssi T
    Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab in primary Sjögren's syndrome: one-year followup.
    Steinfeld SD; Demols P; Appelboom T
    Arthritis Rheum; 2002 Dec; 46(12):3301-3. PubMed ID: 12483735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics in Sjögren's syndrome.
    Skarlis C; Marketos N; Mavragani CP
    Pharmacol Res; 2019 Sep; 147():104389. PubMed ID: 31415917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sjögren Syndrome: Why Do Clinical Trials Fail?
    Fox RI; Fox CM
    Rheum Dis Clin North Am; 2016 Aug; 42(3):519-30. PubMed ID: 27431352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaporins in primary Sjögren's syndrome: comment on the articles by Steinfeld et al.
    Waterman SA; Beroukas D; Hiscock J; Jonsson R; Gordon TP
    Arthritis Rheum; 2003 Apr; 48(4):1167-8. PubMed ID: 12687572
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary Sjögren's syndrome: new clinical and therapeutic concepts.
    Ramos-Casals M; Tzioufas AG; Font J
    Ann Rheum Dis; 2005 Mar; 64(3):347-54. PubMed ID: 15498797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sjögren Syndrome in the Twenty-First Century.
    Scofield RH
    Rheum Dis Clin North Am; 2016 Aug; 42(3):xiii-xiv. PubMed ID: 27431355
    [No Abstract]   [Full Text] [Related]  

  • 20. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.